Flagship, ARCH Close VC Funds Totaling $2.56bn

 
• By Mandy Jackson
  
Generate a summary of this article
Listen to this article
Beta

Flagship Pioneering raised $1.1bn to fund life science companies emerging from Flagship Labs. ARCH, another frequent start-up co-founder, raised two funds totaling $1.46bn to back early-stage biotech.

Business, Technology, Internet and network concept. Young businessman working on a virtual screen of the future and sees the inscription: venture capital
Both Flagship and ARCH focus on company creation and early-stage investments • Source: Shutterstock

Two investment firms that focus on life science companies at their earliest stages said on 2 April that they have raised a total of $2.56bn across three venture capital funds – Flagship Pioneering with a single $1.1bn fund and ARCH Venture Partners with two funds totaling $1.46bn. These new funds may help their investors and limited partners capitalize on the biopharmaceutical industry’s rising profile due to its role in helping with the COVID-19 pandemic.

It is remarkable that two separate firms were able to raise $1bn-plus during a time when economic uncertainty due to...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

SpotifyApple PodcastsWebsite

More from Financing

More from Business

  • How A New Healthcare Dialogue Is Driving Market Access In Mexico

    Companies stand a better chance of securing public reimbursement in Mexico for innovative medicines if they understand changing approaches to healthcare. The shift means the emergence of managed entry agreements and a focus on economic impact, explains AMIIF, Mexico's research-based pharmaceutical industry association.

  • How Novartis Is Elevating CVD Outcomes, Driving ‘Personalized Access’ In APMA

    Novartis’s APMA chief outlines the company’s tailored approach to deliver long-term outcomes, novel access solutions via innovative financing options and shape the CVD disease ecosystem in the extraordinarily diverse region. Partnering to build AI infrastructure is another key prong.

  • India Rare Diseases: Court Shows Path For Policy Action, Funding, Price Issues-- Test-2

    A court order encompassing funding, drug pricing, clinical trials and overall policy implementation aspects is expected to bring about a paradigm shift in the treatment of rare diseases in India. Sarepta, Roche and Sanofi are among the key players that have been part of pricing discussions.